Article Details

First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent | BioSpace

Retrieved on: 2022-04-14 15:18:15

Tags for this article:

Click the tags to see associated articles and topics

First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent | BioSpace. View article details on HISWAI: https://www.biospace.com/article/releases/first-patients-dosed-with-illuccix-telix-s-approved-prostate-cancer-imaging-agent/

Excerpt

INDIANAPOLIS, April 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first commercial doses ...

Article found on: www.biospace.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up